The Conference Forum announces the launch of Cell & Gene Therapy Day on February 27, 2020, in New York City, with a focus on solid tumor immunotherapy data.
NEW YORK (PRWEB) NOVEMBER 19, 2019
The inaugural Cell & Gene Therapy Day takes place February 27, 2020 at the Crowne Plaza Times Square in New York City. The one-day event will be chaired by Dr Aiman Shalabi, VP R&D, Cell and Gene Therapies for GSK, with a diverse group of leaders in the space.
“We are witnessing significant innovation in cell and gene therapies, and we are at a turning point of advancing these technologies for solid tumors,” said Dr Shalabi. “This conference will engage global leaders on a series of scientific, investment landscape, regulatory and manufacturing topics with the ambition of accelerating these treatments to patients with solid cancers.”
Cell & Gene Therapy Day will focus primarily on the promising data and progress for solid tumors.
IO and cell therapy expert Dr Arie Belldegrun, Allogene, is the opening keynote and will kick off the day by addressing advancements in CAR-T cell therapy.
Immunotherapy expert, Dr Crystal Mackall, Director of the Stanford Center for Cancer Cell Therapy at Stanford University School of Medicine, will deliver a cornerstone presentation on new scientific frontiers in cell therapies for solid tumors. Dr Mackall has been a leader in treating hematologic tumors, with extensive work using CAR to target CD19 and CD22 in childhood leukemia.
The day will touch upon several different areas of cell and gene therapy. Dr Peter Marks, Director of the Center for Biologics Evaluation and Research at the Food and Drug Administration, will lead a panel on the evolution of regulatory policy for cell and gene therapy.
IO360 ̊ veteran Dr Ramy Ibrahim, Parker Institute for Cancer Immunotherapy, will address master protocols in cell and gene therapy, and his company’s own innovations in the field. Dr Ibrahim will also lead a discussion on the latest in collaborative development paradigms for cell therapies with Dr Elad Sharon, National Cancer Institute, and Dr Mitch Finer, ElevateBio.
Leaders from Loncor Investments, Cancer Research Institute, IQVIA and the Alliance for Regenerative Medicine will trace through the landscape and evolution of the cell and gene therapy marketplace.
One portion of the day will focus on pivotal developments in solid tumor treatment. The National Institutes of Health’s Dr Stephanie Goff will address tumor-infiltrating lymphocytes as a way of treating cancer. Dr Maria Fardis, Iovance, will speak on TILs as a way targeting individual tumor mutations. Dr Shalabi will return for an update on NY-ESO-1. Dr John Connolly, Tessa Therapeutics, will highlight the prognostic values of antiviral responses and using virus-specific T cells as a solid tumor immunotherapy platform. The day will conclude with debates on combinations with checkpoints, and bedside versus centralized manufacturing.
About Cell & Gene Therapy Day:
Cell & Gene Therapy Day convenes stakeholders spanning the science and business communities to report on the latest cell and gene therapy progress to fight a wider range of cancers beyond hematologic malignancies. Cell & Gene Therapy Day is available an independent one-day program with a luncheon and networking reception, or attendees can register for the three day IO360˚ program, which includes the Cell & Gene Therapy Day. For more information on IO360˚, please click here.
About the Conference Forum:
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. They are committed to creating the best content, exchange of ideas and solutions among peers, as well as providing high-quality networking.
We are witnessing significant innovation in cell and gene therapies, and we are at a turning point of advancing these technologies for solid tumors.
